A growth hormone-releasing hormone antagonist called MZ-4-71 significantly inhibited the growth of two human osteosarcoma (bone cancer) cell lines transplanted into mice by reducing IGF-I levels in both blood and tumor tissue. Conversely, the GHRH agonist sermorelin stimulated tumor growth, highlighting the IGF-I pathway as a potential therapeutic target and suggesting that blocking growth hormone-releasing hormone signaling could be a strategy for treating bone cancers.
Pinski, J; Schally, A V; Groot, K; Halmos, G; Szepeshazi, K; Zarandi, M; Armatis, P